I'm Dr. Iftikhar Kullo a consultant in the Department of Cardiovascular Medicine and the Gonda Vascular Center, and a clinician and investigator at Mayo Clinic in Rochester, Minnesota.
I appreciate this opportunity to talk about electronic MEdical Records and GEnomics, or eMERGE, phase IV Study.
The eMERGE Network is funded by the National Institutes of Health to identify genetic variants related to health and disease and to help implement genomic medicine. The network comprises ten medical institutions across the United States, including Mayo Clinic. And I serve as the Mayo principal investigator.
Currently in its fourth phase, the eMERGE Network is focusing on the genetic risk of common diseases. And we are studying how an individual's genetic makeup and family history affect his or her risk of developing conditions such as heart disease, diabetes and cancer.
Here at Mayo Rochester we are recruiting 2,000 individuals — 1,900 adults and 100 adolescents ages 13-17. Participants in the study will be asked to sign a consent form, complete surveys about their health, and their family's health history, give a blood or saliva sample for DNA testing and allow the study team to access their electronic health record.
Each participant will receive a report called the Genome-Informed Risk Assessment, or GIRA, that summarizes their personal risk for common health conditions. A study team member or a genetic counselor will meet with the participants found to be at high genetic risk. And we'll address any questions or concerns. High genetic risk is defined as a high polygenic risk score or presence of a pathogenic variant in a gene for hereditary breast and ovarian cancer, Lynch syndrome, familial hypercholesterolemia, and atrial fibrillation.
The GIRA results report will also be sent to clinicians as an in-basket message and will be stored in the patient's electronic health record. Participants may reach out the study team and to their clinicians to schedule an appointment to discuss the results if they have questions.
Our ultimate goal in conducting the study is to improve risk prediction for common diseases, informing strategies to prevent or delay their onset and thereby improve health outcomes.
Thank you for watching this video. Should you have any questions related to the study or have a patient in mind who would be interested in participating, please reach out to us via the contact information provided on this website.